KNSA
HEALTHCAREKiniksa Pharmaceuticals Ltd
What's Moving KNSA Today?
No stock-specific AI insight has been generated for KNSA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$60.62
Fundamentals
Trading
KNSA News
22 articles- Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In ViewYahoo Finance·Jun 23, 2026
- Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep goingYahoo Finance·Jun 19, 2026
- Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should KnowYahoo Finance·Jun 16, 2026
- NTLA Posts Strong Additional Phase III Data From HAE Study, Stock UpYahoo Finance·Jun 16, 2026
- ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & EuropeYahoo Finance·Jun 16, 2026
- Kiniksa (KNSA) director receives RSUs and options in equity grantsStock Titan·Jun 3, 2026
- Kiniksa Pharmaceuticals to Present at Upcoming Investor ConferencesYahoo Finance·May 29, 2026
- High Growth Tech Stocks in the US for May 2026Yahoo Finance·May 26, 2026
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyMarketbeat·May 23, 2026
- We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can AchieveYahoo Finance·May 8, 2026
- Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue GuidanceYahoo Finance·May 2, 2026
- Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial ResultsYahoo Finance·May 1, 2026
- Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ...Yahoo Finance·Apr 29, 2026
- Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher TodayThe Motley Fool·Apr 28, 2026
- Kiniksa Pharmaceuticals International Q1 Earnings Call HighlightsMarketbeat·Apr 28, 2026
- Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 28, 2026
- Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio ExecutionYahoo Finance·Apr 28, 2026
- High Growth Tech Stocks To Watch In The US This April 2026Yahoo Finance·Apr 27, 2026
- Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026Yahoo Finance·Apr 23, 2026
- Kiniksa’s Heart’s Home Campaign Puts ARCALYST Growth Prospects In FocusYahoo Finance·Apr 9, 2026
- Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent PericarditisYahoo Finance·Apr 8, 2026
- Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall MarketYahoo Finance·Apr 6, 2026
All 22 articles loaded
Price Data
52-Week Range
$60.62
Fundamentals
Trading
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd. (KNSA) is a pioneering biopharmaceutical company dedicated to addressing significant unmet medical needs through the development of novel therapies. Its lead candidate, KPL-404, is a monoclonal antibody specifically engineered to modulate immune responses, showcasing its potential in treating various autoimmune disorders. With a robust clinical pipeline and strategic partnerships bolstering its research and development efforts, Kiniksa is positioned for sustained growth in the competitive biopharmaceutical landscape. The company's steadfast commitment to innovation and reimagining treatment paradigms presents a compelling opportunity for institutional investors seeking impactful investments in transformative healthcare solutions.